Table 1. Association of patient and tumor characteristics with CHD1L expression.
| Features | CHD1L over-expression | P Value | |
| Absence N(%) | Presence N(%) | ||
| All | 92(51.4) | 87(48.6) | / |
| Age | 0.011* | ||
| <55 | 34(37.0) | 49(56.3) | |
| >55 | 58(63.0) | 38(43.7) | |
| AJCC T Stage | 0.204 | ||
| 1 | 42(45.7) | 47(54.0) | |
| 2 | 48(52.2) | 35(40.2) | |
| 3–4 | 2(2.2) | 5(5.7) | |
| AJCC N Stage | 0.928 | ||
| 0 | 52(56.5) | 50(57.5) | |
| 1 | 24(26.1) | 23(26.4) | |
| 2 | 12(13.0) | 9(10.3) | |
| 3 | 4(4.3) | 5(5.7) | |
| Grade | 0.004* | ||
| 1 | 29(31.5) | 11(12.6) | |
| 2 | 45(48.9) | 46(52.9) | |
| 3 | 18(19.6) | 30(34.5) | |
| ER | 0.264 | ||
| Negative | 26(28.3) | 32(36.8) | |
| Positive | 66(71.7) | 55(63.2) | |
| PR | 0.456 | ||
| Negative | 40(43.5) | 43(49.4) | |
| Positive | 52(56.5) | 44(50.6) | |
| HER2 | 0.037* | ||
| Negative | 80(87.0) | 64(73.6) | |
| Positive | 12(13.0) | 23(26.4) | |
| Ki-67 | 21.0±19.7 | 28.0±24.3 | 0.018* |
| Subtype | 0.146 | ||
| LA | 32(34.8) | 26(29.9) | |
| LB | 34(37.0) | 30(34.5) | |
| TN | 21(22.8) | 17(19.5) | |
| HER2+ | 5(5.4) | 14(16.1) | |
*, statistically significant.
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.